A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan (ProPuP)

February 6, 2026 updated by: Janssen Pharmaceutical K.K.

Registry of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan

The purpose of this study is to describe the treatment patterns of participants receiving systemic treatment for of palmoplantar pustulosis (PPP) in Japan.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This is a retrospective study where the historical data on PPP therapy will also be used prior to Visit 1 (baseline).

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
276

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Japan
      • Akita, Japan, 010-8543
        • Akita University Hospital
      • Bunkyō City, Japan, 113 8431
        • Juntendo University Hospital
      • Fukuoka, Japan, 812 8582
        • Kyushu University Hospital
      • Fukushima, Japan, 960 1295
        • Fukushima Medical University Hospital
      • Hamamatsu, Japan, 431-3192
        • Hamamatsu University Hospital
      • Hirakata, Japan, 573 1191
        • Kansai Medical University Hospital
      • Hiroshima, Japan, 731-0293
        • Hiroshima City Asa Citizens Hospital
      • Hiroshima, Japan, 733-0032
        • Seiwakai Hiroshima Clinic
      • Hokkaido, Japan, 060-0033
        • JR Sapporo Hospital
      • Hyōgo, Japan, 6751392
        • Kita-harima Medical Center
      • Itabashi Ku, Japan, 173 8606
        • Teikyo University Hospital
      • Kita-ku, Japan, 700-8511
        • Okayama Saiseikai General Hospital
      • Kochi, Japan, 780-8522
        • Chikamori Hospital
      • Kochi, Japan, 783-8505
        • Kochi Medical School Hospital
      • Kofu, Japan, 400-8506
        • Yamanashi Prefectural Central Hospital
      • Kurashiki-shi, Japan, 710-8522
        • Kurashiki Medical Center
      • Kurume, Japan, 830-0011
        • Kurume University Hospital
      • Kuwana, Japan, 511 0061
        • Kuwana City Medical Center
      • Kyoto, Japan, 606-8507
        • Kyoto University Hospital
      • Kyoto, Japan, 612-8555
        • National Hospital Organization Kyoto Medical Center
      • Matsumoto, Japan, 390 8621
        • Shinshu University Hospital
      • Meguro-ku, Japan, 153-8515
        • Toho University Medical Center, Ohashi Hospital
      • Nagoya, Japan, 467 8602
        • Nagoya City University Hospital
      • Nishinomiya, Japan, 663-8501
        • The Hospital of Hyogo College of Medicine
      • Okayama, Japan, 700 8558
        • Okayama University Hospital
      • Sapporo, Japan, 060-8648
        • Hokkaido University Hospital
      • Sasebo, Japan, 857 1195
        • Sasebo Chuo Hospital
      • Sendai, Japan, 980 8574
        • Tohoku University Hospital
      • Shinjuku-ku, Japan, 160-8582
        • Keio University Hospital
      • Takamatsu, Japan, 760 0017
        • Takamatsu Red Cross Hospital
      • Tokyo, Japan, 160-0023
        • Tokyo Medical University Hospital
      • Tokyo, Japan, 193-0998
        • Tokyo Medical University Hachioji Medical Center
      • Tokyo, Japan, 104 8560
        • St. Luke's International Hospital
      • Toyoake, Japan, 470-1192
        • Fujita Health University Hospital
      • Tōon, Japan, 791-0295
        • Ehime University Hospital
      • Yokosuka, Japan, 238 8558
        • Yokosuka Kyosai Hospital
      • Ōita, Japan, 879-5593
        • Oita University Hospital
      • Ōsaka-sayama, Japan, 589-8511
        • Kindai University Hospital
      • Ōtsu, Japan, 520-2192
        • Shiga University Of Medical Science Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

20 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

Participants observed in this study newly initiated/will be newly initiating a systemic therapy for their PPP/pustulotic arthro-osteitis (PAO) - either as their first systemic therapy or as a switch from, or an addition to a previous therapy, having had an inadequate response and/or intolerant to prior PPP/PAO therapy. Participants will be treated in accordance with routine clinical practice in Japan in the outpatient specialist care setting.

Description

Inclusion Criteria:

  • Must have a confirmed diagnosis of palmoplantar pustulosis (PPP) and/or pustulotic arthro-osteitis (PAO) in accordance with local clinical practice
  • Has previously been prescribed treatment for PPP/PAO
  • A decision has been made by the treating physician and the participant to commence treatment with a systemic PPP/PAO therapy, having been deemed to have an inadequate response to previous therapy (New users are defined as those participants to commence treatment on baseline visit date. Existing users are defined as those who commenced treatment prior to the baseline visit since 01 November 2019.)
  • Must sign a participation agreement/informed consent form allowing data collection and source data verification in accordance with local requirements

Exclusion Criteria:

  • Are receiving, or have received within the past 3 months, anti-inflammatory or analgesic systemic therapy such as oral corticosteroid, disease modifying antirheumatic drug (DMARDs), non-steroidal anti-inflammatory drugs, opioids, phosphodiesterase 4 (PDE4) inhibitor, or biologics for any other indication (for example, psoriasis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and asthma)
  • Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 3 months before the start of the study or the first data collection time point
  • Participation in an investigational study
  • Participation in another observational study for guselkumab (including a post marketing surveillance study)
  • If the only treatment they have received for PPP has been antibiotics

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Participants With Palmoplantar pustulosis (PPP)
Participants treated with a new systemic therapy for their PPP, having had an inadequate response to a prior PPP therapy either as their first systemic therapy or as a switch from, or addition to, a previous systemic therapy will be observed. Participants will be treated in accordance with routine clinical practice in Japan in the outpatient specialist care setting. The primary data source for this study will be the medical records of each participant.
Other: No intervention
No intervention will be administered as a part of this study. Both retrospective and prospective data will be collected. The retrospective data will be collected through participant charts and prospective data will be collected in accordance with clinical practice at the participant's clinic visits.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Percentage of Participants who Remain on Their 'Index Systemic' Therapy
Time Frame: Up to 4.5 Years
Percentage of participants who remain on their 'index systemic' therapy will be reported.
Up to 4.5 Years
Percentage of Participants Ceasing Their 'Index Systemic' Therapy
Time Frame: Up to 4.5 Years
Percentage of participants ceasing their 'index systemic' therapy will be reported.
Up to 4.5 Years
Time to Cessation of Index Systemic Therapy From Baseline
Time Frame: Baseline, Up to 4.5 Years
Time to cessation of index systemic therapy from baseline will be reported.
Baseline, Up to 4.5 Years

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Percentage of Participants Receiving Each 'Index Systemic' Therapy
Time Frame: Baseline
Percentage of participants receiving each 'Index Systemic' therapy will be reported.
Baseline
Mean and Distribution of Dermatology Life Quality Index (DLQI) Scores at Baseline
Time Frame: Baseline
Mean and distribution of DLQI scores at baseline will be reported. DLQI instrument consists of 10 questions covering six domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and bother with psoriasis treatment). The response options range from 0, not affected at all, to 3, very much affected. This gives an overall range of 0 to 30 where lower scores mean better quality of life.
Baseline
Mean and Distribution of European Quality of Life (EuroQol) Group, 5-Dimension, 5-Level (EQ-5D-5L) Scores at Baseline
Time Frame: Baseline
Mean and distribution of EQ-5D-5L scores at baseline will be reported. EQ-5D-5L is a descriptive system of health-related quality of life states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of five responses. The responses record five levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension. A lower score indicates worse health.
Baseline
Mean and Distribution of Work Productivity and Activity Impairment: General Health (WPAI:GH) Scores at Baseline
Time Frame: Baseline
Mean and distribution of WPAI:GH scores at baseline will be reported. WPAI:GH questionnaire is a validated instrument to measure impairments in both paid work and unpaid work. It measures absenteeism, presenteeism as well as the impairments in unpaid activity because of health problem during the past seven days. It consists of 6-item questionnaire looks at the effect of health problems on ability to work and perform regular activities. The WPAI yields 4 types of scores: absenteeism (work time missed), presenteeism (impairment at work / reduced on-the-job effectiveness), work productivity loss (overall work impairment / absenteeism plus presenteeism) and activity impairment. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes.
Baseline
Percentage of Participants Adding a Concurrent Systemic Treatment to their 'Index Systemic' Therapy
Time Frame: Baseline and Every 6 Months Up to 4.5 Years
Percentage of participants adding a concurrent systemic treatment to their 'index systemic' therapy will be reported.
Baseline and Every 6 Months Up to 4.5 Years
Percentage of Participants Ceasing a Concurrent Systemic Treatment to their 'Index Systemic' Therapy
Time Frame: Baseline and Every 6 Months Up to 4.5 Years
Percentage of participants ceasing a concurrent systemic treatment to their 'index systemic' therapy will be reported.
Baseline and Every 6 Months Up to 4.5 Years
Time to Addition of a Concurrent Systemic Treatment to 'Index Systemic' Therapy
Time Frame: Baseline and Every 6 Months Up to 4.5 Years
Time to addition of a concurrent systemic treatment to 'index systemic' therapy will be reported.
Baseline and Every 6 Months Up to 4.5 Years
Time to Ceasing of a Concurrent Systemic Treatment to 'Index Systemic' Therapy
Time Frame: Baseline and Every 6 Months Up to 4.5 Years
Time to ceasing of a concurrent systemic treatment to 'index systemic' therapy will be reported.
Baseline and Every 6 Months Up to 4.5 Years
Percentage of Participants Changing the Dosage of their 'Index Systemic' Therapy
Time Frame: Baseline and Every 6 Months Up to 4.5 Years
Percentage of participants changing the dosage of their 'index systemic' therapy will be reported.
Baseline and Every 6 Months Up to 4.5 Years
Percentage of Participants Adding a Concurrent Non-Systemic Therapy to their 'Index Systemic' Therapy
Time Frame: Baseline and Every 6 Months Up to 4.5 Years
Percentage of participants adding a concurrent non-systemic therapy to their 'index systemic' therapy will be reported.
Baseline and Every 6 Months Up to 4.5 Years
Percentage of Participants Ceasing a Concurrent Non-Systemic Therapy to their 'Index Systemic' Therapy
Time Frame: Baseline and Every 6 Months Up to 4.5 Years
Percentage of participants ceasing a concurrent non-systemic therapy to their 'index systemic' therapy will be reported.
Baseline and Every 6 Months Up to 4.5 Years
Percentage of Participants Switching to a First Subsequent Systemic Therapy Within the Follow-up Period
Time Frame: Every 6 Months Up to 4.5 Years
Percentage of participants switching to a first subsequent systemic therapy within the follow-up period will be reported.
Every 6 Months Up to 4.5 Years
Time to Commencement of First Subsequent Systemic Therapy From Baseline
Time Frame: Baseline and Every 6 Months Up to 4.5 Years
Time to commencement of first subsequent systemic therapy from baseline will be reported.
Baseline and Every 6 Months Up to 4.5 Years
Percentage of Participants Switching to a Second Subsequent Systemic Therapy Within the Follow-up Period
Time Frame: Every 6 Months Up to 4.5 Years
Percentage of participants switching to a second subsequent systemic therapy within the follow-up period will be reported.
Every 6 Months Up to 4.5 Years
Time to Commencement of Second Subsequent Systemic Therapy From Baseline
Time Frame: Baseline and Every 6 Months Up to 4.5 Years
Time to commencement of second subsequent systemic therapy from baseline will be reported.
Baseline and Every 6 Months Up to 4.5 Years
Mean and Distribution of Health Assessment Questionnaire-Disability Index (HAQ-DI) Scores at Baseline
Time Frame: Baseline
Mean and distribution of HAQ-DI scores at baseline will be reported. The Disability Index of the Health Assessment Questionnaire (HAQ-DI) assesses the functional status of the participant. This 20-question instrument assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area where lower scores are indicative of better functioning.
Baseline
Percentage of Participants with a Physician's Global Assessment (PGA) Score of 1 or Less (0 or 1)
Time Frame: Baseline and Every 6 Months Up to 4.5 Years
Percentage of participants with a PGA score of 1 or less (0 or 1) will be reported. The PGA is used to determine the participant's overall palmoplantar pustulosis lesions at a given time point. Overall lesions will be graded based on the scale where, 0 = clear;1 = almost clear; 2 = Mild; 3 = Moderate; 4 = Severe; 5 = Very severe.
Baseline and Every 6 Months Up to 4.5 Years
Change From Baseline in PGA Score
Time Frame: Baseline and Every 6 Months Up to 4.5 Years
Change From baseline in PGA score will be reported. The PGA is used to determine the participant's overall palmoplantar pustulosis lesions at a given time point. Overall lesions will be graded based on the scale where, 0 = clear;1 = almost clear; 2 = Mild; 3 = Moderate; 4 = Severe; 5 = Very severe.
Baseline and Every 6 Months Up to 4.5 Years
Change from Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Score
Time Frame: Baseline and Every 6 Months Up to 4.5 Years
The PPPASI assesses the severity of palmoplantar pustulosis lesions and their response to therapy. In the PPPASI system, the palms and soles are divided into 4 regions: the right palm, left palm, right sole, and left sole, which account for 20 percent (%), 20%, 30%, and 30%, respectively, of the total surface area of the palms and soles. Each of these areas is assessed separately for erythema, pustules/vesicle and desquamation/scale, which are each rated on a scale of 0 to 4. The PPPASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
Baseline and Every 6 Months Up to 4.5 Years
Change From Baseline in Pain Visual Analogue Scale (Pain-VAS) Score
Time Frame: Baseline and Every 6 Months Up to 4.5 Years
Change from baseline in Pain-VAS score will be reported. Pain-VAS is used to measure subjective pain status. It is a unilateral scale anchored at 0 (no pain) and 10 (worst pain imaginable).
Baseline and Every 6 Months Up to 4.5 Years
Change in Primary Location of Pain
Time Frame: Baseline and Every 6 Months Up to 4.5 Years
Change in primary location of pain will be reported.
Baseline and Every 6 Months Up to 4.5 Years
Change From Baseline in DLQI Score
Time Frame: Baseline and Every 6 Months Up to 4.5 Years
Change from baseline in DLQI score will be reported. DLQI instrument consists of 10 questions covering six domains (symptoms and feelings, daily activities, leisure, work and school, personal relationships, and bother with psoriasis treatment). The response options range from 0, not affected at all, to 3, very much affected. This gives an overall range of 0 to 30 where lower scores mean better quality of life.
Baseline and Every 6 Months Up to 4.5 Years
Change From Baseline in EQ5D-5L Index Score
Time Frame: Baseline and Every 6 Months Up to 4.5 Years
Change from baseline in EQ5D-5L index score will be reported. The EQ-5D-5L is a descriptive system of health-related quality of life states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of five responses. The responses record five levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension.
Baseline and Every 6 Months Up to 4.5 Years
Change from Baseline in HAQ-DI Index Score
Time Frame: Baseline and Every 6 Months Up to .4.5 Years
Change from baseline in HAQ-DI score will be reported. The HAQ-DI assesses the functional status of the participant. This 20-question instrument assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area where lower scores are indicative of better functioning.
Baseline and Every 6 Months Up to .4.5 Years
Change from Baseline in Work Productivity and Activity Impairment questionnaire (WPAI)
Time Frame: Baseline and Every 6 Months Up to 4.5 Years
Change from baseline in WPAI will be reported. WPAI questionnaire is a validated instrument to measure impairments in both paid work and unpaid work. It measures absenteeism, presenteeism as well as the impairments in unpaid activity because of health problem during the past seven days. The higher the score the greater impact on productivity.
Baseline and Every 6 Months Up to 4.5 Years
Percentage of Participants with Adverse Events (AEs) and serious Adverse Events (SAEs)
Time Frame: Up to 4.5 Years
Percentage of participants with adverse events and serious Adverse Events will be reported. An adverse event is any untoward medical occurrence in a participant administered a medicinal (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the treatment. An adverse event can be any unfavorable and unintended sign (including an abnormal finding or lack of expected pharmacological action), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to that medicinal product.
Up to 4.5 Years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Janssen Pharmaceutical K.K.

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Janssen Pharmaceutical K.K., Japan Clinical Trial, Janssen Pharmaceutical K.K.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 22, 2021

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 27, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 27, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 2, 2020

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 2, 2020

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 7, 2020

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 10, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 6, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
February 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CR108811
  • CNTO1959PAP4001 (Other Identifier: Janssen Research & Development, LLC)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Palmoplantar Pustulosis

Clinical Trials on No intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings